A Proof-of-Concept, Open Label Study to Assess the Efficacy, Safety, Tolerability and Pharmacokinetics of Single Doses of DSM265 in Adult Patients With Acute, Uncomplicated Plasmodium Falciparum or Vivax Malaria Mono-Infection Over a 35-Day-Extended Observation Period

Trial Profile

A Proof-of-Concept, Open Label Study to Assess the Efficacy, Safety, Tolerability and Pharmacokinetics of Single Doses of DSM265 in Adult Patients With Acute, Uncomplicated Plasmodium Falciparum or Vivax Malaria Mono-Infection Over a 35-Day-Extended Observation Period

Completed
Phase of Trial: Phase II

Latest Information Update: 12 Feb 2016

At a glance

  • Drugs DSM 265 (Primary)
  • Indications Malaria
  • Focus Pharmacokinetics; Therapeutic Use
  • Sponsors Medicines for Malaria Venture
  • Most Recent Events

    • 29 Jan 2016 Status changed from active, no longer recruiting to completed, according to ClinicalTrials.gov record.
    • 04 Dec 2015 Status changed from recruiting to active, no longer recruiting, according to ClinicalTrials.gov record.
    • 16 Mar 2015 Status changed from not yet recruiting to recruiting as reported by ClinicalTrials.gov record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top